Pharmacokinetics and Pharmacodynamics of LCZ696, a Novel Dual‐Acting Angiotensin Receptor—Neprilysin Inhibitor (ARNi)

Gu, Jessie; Noè, Adele; Chandra, Priya; Al‐Fayoumi, Suliman; Ligueros‐Saylan, Monica; Sarangapani, R.; Maahs, Suzanne; M. Ksander, Gary; F. Rigel, Dean; Y. Jeng, Arco; Lin, Tsu‐Han; Zheng, Weiyi; P. Dole, William

doi:10.1177/0091270009343932

Public

Pharmacokinetics and Pharmacodynamics of LCZ696, a Novel Dual‐Acting Angiotensin Receptor—Neprilysin Inhibitor (ARNi)

Published in The Journal of Clinical Pharmacology • Nov 23, 2009

Authors:

Jessie Gu

Adele Noè

Priya Chandra

Abstract

Angiotensin receptor blockade and neprilysin (NEP) inhibition together offer potential benefits for the treatment of hypertension and heart failure. LCZ696 is a novel single molecule comprising molecular moieties of valsartan and NEP inhibitor prodrug AHU377 (1:1 ratio). Oral administration of LCZ69...

Subject

Valsartan

Neprilysin

Pharmacology

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!